Pharmicell Co: Q1 FY2026 revenue and net income surged, driven by Bio-Chemical sales and robust margins

About this update from Pharmicell Co., Ltd

Q1 FY2026 revenue rose to KRW 36.7 billion, with net income at KRW 11.7 billion and strong growth in the Bio-Chemical segment. Major investments in new production capacity and ongoing clinical trials support future growth, while risk management and dividend policies remain robust.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmicell Co., Ltd